Abstract
The aim of this study was to compare quantitative polymerase chain reaction (qPCR) with immunohistochemistry (IHC) for the detection of Her-2 in gastric cancer, and to investigate the correlation between the expression levels of human epidermal growth factor receptor 2 (Her-2) and clinical features. Clinical data from 426 cases of gastric cancer were collected. Her-2 expression levels in cancerous tissue were detected using IHC, and the Her-2/neu gene expression levels were determined by qPCR. The correlation between the expression level of Her-2 and clinical features was investigated. The positive expression rate of Her-2 in cancerous tissue detected using qPCR and IHC was 11.17% (46/412) and 13.38% (57/426), respectively. The positive expression of the Her-2 protein/gene was significantly correlated with the depth of invasion and lymphatic metastasis, as well as the TNM stage (P<0.05). No significant correlation was identified between positive expression of the Her-2 protein/gene and tumor location, age, gender, differentiation degree and Lauren classification (P>0.05). The diagnostic consistency was good between the two methods (κ=0.828). The results indicate that the expression of Her-2/neu is closely associated with the development of gastric cancer. qPCR is a convenient, objective and efficient method, which may be used as an alternative to IHC or fluorescence in situ hybridization for the detection of Her-2/neu gene.
Highlights
Gastric cancer is the most common malignant tumor of the digestive system and it is the second most lethal cancer worldwide [1]
The expression of human epidermal growth factor receptor 2 (Her‐2)/neu was significantly correlated with the depth of invasion, lymphatic metastasis and TNM stage (P
Her‐2/neu is located on human chromosome 17q21 and is a member of the epidermal growth factor receptor (EGFR) family
Summary
Gastric cancer is the most common malignant tumor of the digestive system and it is the second most lethal cancer worldwide [1]. The prevalence of gastric cancer differs regionally, and ~70% of cases occur in developing countries [2,3,4]. Park et al [6] demonstrated that Her‐2 is an independent prognostic factor of gastric cancer. Her‐2 is usually detected using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which each have advantages and disadvantages. The investigation of novel methods is necessary. 426 cases of gastric cancer, all pathogenically confirmed, were collected. Her‐2 expression in tumor tissue was examined using IHC, and the Her‐2/neu gene expression was examined by quantitative polymerase chain reaction (qPCR). The aim of this study was to provide a novel method for the detection of Her‐2/neu gene in gastric cancer tissues
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
